Leukemia clinical trials in Arkansas

14 actively recruiting leukemia trials at 3 sites across Arkansas.

Data from ClinicalTrials.gov · last refreshed 2026-11-09

Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group

NCT ID: NCT03959085

Sites in Arkansas:

Arkansas Children's Hospital — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …

Sponsor: Children's Oncology Group

NCT ID: NCT04293562

Sites in Arkansas:

Arkansas Children's Hospital — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT03739814

Sites in Arkansas:

Mercy Hospital Fort Smith — Fort Smith, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554406

Sites in Arkansas:

University of Arkansas for Medical Sciences — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04546399

Sites in Arkansas:

Arkansas Children's Hospital — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC

NCT ID: NCT04726241

Sites in Arkansas:

Arkansas Children's Hospital — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06124157

Sites in Arkansas:

Arkansas Children's Hospital — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06317662

Sites in Arkansas:

Arkansas Children's Hospital — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transform…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT04728893

Sites in Arkansas:

Highlands Oncology Group ( Site 2728) — Springdale, Arkansas

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Arkansas:

Mercy Hospital Fort Smith — Fort Smith, Arkansas
CARTI Cancer Center — Little Rock, Arkansas

View on ClinicalTrials.gov →

Recruiting Network

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated i…

Sponsor: Children's Oncology Group

NCT ID: NCT00736749

Sites in Arkansas:

Arkansas Children's Hospital — Little Rock, Arkansas
University of Arkansas for Medical Sciences — Little Rock, Arkansas

View on ClinicalTrials.gov →

Recruiting Network

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…

Sponsor: Children's Oncology Group

NCT ID: NCT01790152

Sites in Arkansas:

Arkansas Children's Hospital — Little Rock, Arkansas

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Arkansas:

Massive Bio SYNERGY-AI site — Little Rock, Arkansas

View on ClinicalTrials.gov →

Recruiting Academic/Other

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are: * Eval…

Sponsor: Arkansas Children's Hospital Research Institute

NCT ID: NCT07422337

Sites in Arkansas:

Arkansas Children's — Little Rock, Arkansas
Arkansas Children's Northwest — Springdale, Arkansas

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09